Venture Life Group Finalizes Acquisition of 200,000 Shares at 70.12p Each Under Ongoing Buyback Program

Details of Share Repurchase and Execution

On 23 July 2026, Venture Life Group plc completed the acquisition of 200,000 ordinary shares (0.3 pence each) through its broker Cavendish Capital Markets Limited. All shares were purchased at a uniform volume-weighted average price of 70.12 pence per share, with the lowest and highest prices matching this figure. The transaction was executed on the AIM exchange (AIMX venue) as a single block purchase at 16:35, rather than multiple smaller trades throughout the day.

This buyback is part of the larger share repurchase programme initiated on 30 September 2025, underscoring the company’s commitment to capital management. By holding these shares as treasury shares instead of cancelling them immediately, Venture Life retains strategic flexibility. Treasury shares can be reissued for acquisitions, employee share schemes, or other corporate purposes, or may be cancelled later to reduce share capital, allowing management to optimize capital allocation while returning value to shareholders.

Effect on Share Capital Structure and Voting Rights

Following this repurchase, Venture Life’s share capital now comprises 128,860,145 ordinary shares, including 8,146,904 held in treasury. Treasury shares do not carry voting rights, so the total voting rights outstanding are 120,713,241 ordinary shares. This figure is critical for regulatory and governance purposes, serving as the basis for calculating disclosure thresholds under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

The reduction in voting rights slightly increases the percentage thresholds at which shareholders must disclose holdings, impacting notification obligations for substantial shareholders. This outcome is typical of share buyback programmes and reflects standard capital management practices among listed companies.

Venture Life’s Focus on Healthy Longevity and Consumer Healthcare Innovation

Venture Life Group plc is an international consumer self-care company specializing in proactive healthy longevity, product innovation, and commercialization within the global consumer healthcare sector. Headquartered in the UK, the company offers a diverse range of healthcare and wellness brands targeting specific consumer needs. These include Balance Activ (women’s intimate healthcare), Earol (ear, nose, and throat care), Lift and Glucogel (energy management and glucose support, especially for hypoglycaemia), and Health & Her (supporting women through hormonal lifecycle stages).

The company’s portfolio focuses on consumer-recommended self-care solutions typically advised by pharmacists or healthcare professionals rather than prescription-only medicines. This positioning enables distribution across health and beauty retailers, pharmacies, grocery multiples, and growing e-commerce platforms. Venture Life employs a mixed distribution model, supplying directly to retailers in key markets such as the UK, Ireland, and the US, while partnering with international distributors elsewhere to expand geographic reach efficiently.

Geographic Distribution and Retail Channel Strategy

Venture Life’s distribution strategy is tiered by region. In the UK, Ireland, and the US, the company supplies products directly to retailers, maintaining control over customer relationships, pricing, and brand representation. This direct distribution model typically yields higher margins but requires dedicated sales and distribution infrastructure in these core markets.

Outside these territories, the company relies on international distribution partners who manage local market expertise, regulatory compliance, logistics, and customer relations. This approach allows Venture Life to scale globally while minimizing fixed costs and operational complexity. The success of this strategy depends on the capabilities and commitment of these partners but has enabled the company to establish a broad international footprint.

Healthcare Practitioner Recommendations and Market Positioning

A key aspect of Venture Life’s market approach is its reliance on healthcare practitioner recommendations—particularly pharmacists—rather than direct consumer marketing or prescription models. Products such as Balance Activ, Earol, Lift, Glucogel, and Health & Her are typically recommended by qualified professionals for specific health conditions or lifecycle needs.

This strategy enhances credibility and trust, supporting premium pricing and brand loyalty compared to mass-market consumer healthcare products. Practitioner endorsement also offers protection against unbranded or private-label competition, as healthcare professionals tend to recommend established, trusted brands.

The focus on practitioner recommendations aligns with healthcare system incentives in developed markets where pharmacists and healthcare providers are trusted advisors. Targeting women’s intimate health, ENT care, energy and glucose management, and hormonal lifecycle support addresses consumer health needs that benefit from professional guidance and are suited to retail and e-commerce distribution rather than prescription-only channels.

Treasury Shares and Corporate Flexibility

By retaining the repurchased shares as treasury shares instead of cancelling them, Venture Life’s board preserves capital management flexibility. Treasury shares can be reissued later for acquisitions, employee incentive schemes, or opportunistic capital raising without requiring new shareholder approval, unlike issuing new shares.

Currently holding 8,146,904 treasury shares, the company maintains tactical optionality to deploy these shares for value-accretive purposes or strategic transactions. While treasury shares represent capital retained within the company rather than returned to shareholders, they provide management with tools to respond swiftly to corporate opportunities.

Share Buyback Programme and Capital Allocation Strategy

This 200,000-share repurchase on 23 July 2026 is part of the ongoing buyback programme initiated on 30 September 2025. Details regarding the total programme size, duration, or prior repurchases have not been disclosed. The continuation of buybacks suggests management views repurchasing shares at current market prices as an effective use of cash compared to alternatives such as dividends, debt repayment, or reinvestment.

Share buybacks typically reflect management’s belief that shares are undervalued or that returning capital via repurchases balances financial flexibility with shareholder rewards. While this specific tranche was executed at 70.12 pence per share, the overall programme’s scope and timeline remain unspecified, leaving open the possibility of further repurchases subject to market conditions and company discretion.

Regulatory Compliance and Disclosure

This announcement fulfills Venture Life’s regulatory obligations under AIM listing rules, providing transparency on share repurchase quantities, prices, timing, and execution venue. The single-price, block purchase nature of the transaction is clearly disclosed, supporting market fairness and transparency.

The update on voting rights to 120,713,241 ordinary shares is crucial for shareholders to assess their regulatory disclosure requirements under the FCA’s Disclosure Guidance and Transparency Rules. This information assists large shareholders and institutional investors in monitoring their notifiable interests and complying with disclosure thresholds.

Market Impact and Shareholder Implications

The immediate effect of this transaction on Venture Life’s share price is not detailed in the announcement. The purchase price of 70.12 pence per share reflects the executed price on 23 July 2026, but without contemporaneous share price data, investors cannot determine if this represented a premium or discount.

The 200,000 shares repurchased represent a meaningful volume relative to typical AIM trading activity but the impact on market capitalization depends on total issued shares and prevailing share price. Investors should consider this buyback within the broader context of Venture Life’s financial health, growth prospects, and capital allocation priorities when evaluating shareholder value implications.